Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
KPTI
KPTI
Nasdaq
Health Technology
Pharmaceuticals: Major
7.10
USD
-0.08
-1.11%
Open: 07-23 13:42 (UTC+0)

KPTI Key Statistics

High
7.16
Open
7.14
Volume
68.18K
Low
7.00
Prev. Close
7.18
Trading Value
483.12K
52-Week High
10.99
Relative Volume
0.105
Amplitude (%)
2.09%
52-Week Low
3.65
Turnover Rate
0.30%
Market Cap
162.71M
P/E Ratio (TTM)
--
P/E Ratio (Annual)
--
P/B Ratio
-0.61
P/S Ratio
1.08
Earnings Per Share (EPS)
-15.087
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
22.66M
Currency Unit
USD

KPTI Price Performance

7 day
30 day
90 day
180 day
Year to date
1 Year
KPTI Money Flow Distribution
KPTI Daily Short Sale Volume
KPTI Short Interest History
As of 2026-07-23, the Karyopharm Therapeutics Inc. (KPTI) stock price today is 7.1. Based on this price, the company has a market capitalization of $162.71M, with a P/E ratio of --. On 2026-07-23, KPTI traded between 7.00 and 7.16. Today’s stock price is 1.43% above the daily low and 0.84% below the daily high, placing KPTI in the upper range of its most recent trading range. Trading volume currently stands at 68.18K, compared with an average daily volume of 648.75K. This suggests that trading activity is significantly below its usual level than usual. Over the past year, Karyopharm Therapeutics Inc. shares have traded between 3.65 and 10.99. At today’s price, KPTI is 94.52% above its 52-week low and 35.40% below its 52-week high.
Company Name
Karyopharm Therapeutics Inc.
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchanges
Nasdaq
Number of Employees
228
Lot Size
100
Official Website
Currency Unit
USD
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

KPTI FAQ